Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefan Fuxius

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Journal of Pharmaceutical and Biomedical Analysis|September 23, 2022
Development and validation of a bioanalytical method for the quantification of axitinib from plasma and capillary blood using volumetric absorptive microsampling (VAMS) and on-line solid phase extraction (SPE) LC-MSPatrick Opitz, Sebastian Zimmermann, Anna M Mc Laughlin, et al.
Anticancer Research|July 24, 2010
A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancerJoachim Drevs, Michael Medinger, Klaus Mross, et al.
Journal of Cancer|April 4, 2017
Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German CentersStefanie Zschäbitz, Sonia Vallet, Boris Hadaschik, et al.
Oncology Research and Treatment|December 23, 2014
Quality of life under capecitabine (Xeloda®) in patients with metastatic breast cancer: data from a german non-interventional surveillance studyVolkmar Müller, Stefan Fuxius, Claus-Christoph Steffens, et al.
In Vivo (Athens, Greece)|January 2, 2023
Usage of Complementary and Alternative Methods, Lifestyle, and Psychological Variables in Cancer CareCatalina Hoppe, Jens Buntzel, Ludwig Fischer VON Weikersthal, et al.
Journal of Cancer Research and Clinical Oncology|April 25, 2012
A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysisSven Mahner, Gülten Oskay-Özcelik, Elke Heidrich-Lorsbach, et al.
Cancer Research|July 19, 2002
PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imagingJoachim Drevs, Ralph Müller-Driver, Christine Wittig, et al.
Oncology Research and Treatment|February 7, 2024
Spirituality in Oncology: Relations between Spirituality, Its Facets, and Psychological and Demographic Factors in Cancer Patients in GermanyGina Heuschkel, Ludwig Fischer von Weikersthal, Constanze Junghans, et al.
Anticancer Research|October 3, 2022
Retrospective Analysis of Treatment Pathways in Patients With BRAF<sup>V600E</sup>-mutant Metastatic Colorectal Carcinoma - MORSE<sup>CRC</sup>Armin Gerger, Wolfgang Eisterer, Stefan Fuxius, et al.
Gynecologic Oncology Research and Practice|March 14, 2017
Preference of elderly patients' to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trialRadoslav Chekerov, Philipp Harter, Stefan Fuxius, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Journal of Pharmaceutical and Biomedical Analysis|September 23, 2022
Development and validation of a bioanalytical method for the quantification of axitinib from plasma and capillary blood using volumetric absorptive microsampling (VAMS) and on-line solid phase extraction (SPE) LC-MSPatrick Opitz, Sebastian Zimmermann, Anna M Mc Laughlin, et al.
Anticancer Research|July 24, 2010
A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancerJoachim Drevs, Michael Medinger, Klaus Mross, et al.
Journal of Cancer|April 4, 2017
Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German CentersStefanie Zschäbitz, Sonia Vallet, Boris Hadaschik, et al.
Oncology Research and Treatment|December 23, 2014
Quality of life under capecitabine (Xeloda®) in patients with metastatic breast cancer: data from a german non-interventional surveillance studyVolkmar Müller, Stefan Fuxius, Claus-Christoph Steffens, et al.
In Vivo (Athens, Greece)|January 2, 2023
Usage of Complementary and Alternative Methods, Lifestyle, and Psychological Variables in Cancer CareCatalina Hoppe, Jens Buntzel, Ludwig Fischer VON Weikersthal, et al.
Journal of Cancer Research and Clinical Oncology|April 25, 2012
A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysisSven Mahner, Gülten Oskay-Özcelik, Elke Heidrich-Lorsbach, et al.
Cancer Research|July 19, 2002
PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imagingJoachim Drevs, Ralph Müller-Driver, Christine Wittig, et al.
Oncology Research and Treatment|February 7, 2024
Spirituality in Oncology: Relations between Spirituality, Its Facets, and Psychological and Demographic Factors in Cancer Patients in GermanyGina Heuschkel, Ludwig Fischer von Weikersthal, Constanze Junghans, et al.
Anticancer Research|October 3, 2022
Retrospective Analysis of Treatment Pathways in Patients With BRAF<sup>V600E</sup>-mutant Metastatic Colorectal Carcinoma - MORSE<sup>CRC</sup>Armin Gerger, Wolfgang Eisterer, Stefan Fuxius, et al.
Gynecologic Oncology Research and Practice|March 14, 2017
Preference of elderly patients' to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trialRadoslav Chekerov, Philipp Harter, Stefan Fuxius, et al.
Pageof 3